Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. PharmAust Limited
  6. Summary
    PAA   AU000000PAA1

PHARMAUST LIMITED

(PAA)
 SummaryChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
0.088 0.089 0.088 0.09 0.087 Last
214712 42579 171335 103514 204005 Volume
-3.30% +1.14% -1.12% +2.27% -3.33% Change
Estimated financial data (e)
Sales 2020 4,12 M 2,99 M 2,99 M
Net income 2020 -1,36 M -0,99 M -0,99 M
Net cash position 2020 1,41 M 1,03 M 1,03 M
P/E ratio 2020 -33,7x
Yield 2020 -
Sales 2021 3,66 M 2,66 M 2,66 M
Net income 2021 -1,34 M -0,97 M -0,97 M
Net cash position 2021 1,75 M 1,27 M 1,27 M
P/E ratio 2021 -21,5x
Yield 2021 -
Capitalization 27,6 M 20,1 M 20,0 M
EV / Sales 2020 11,0x
EV / Sales 2021 7,40x
Nbr of Employees -
Free-Float 63,9%
More Financials
Company
Pharmaust Limited is an Australia-based clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for cancer, neurodegenerative diseases and viral infections in humans and cancer for pet dogs. The Company's lead candidate, monepantel (MPL), is a small molecule drug primarily being developed as a safe and potent treatment for cancer. The MPL can also be used for neurodegenerative... 
Sector
Pharmaceuticals
Calendar
03/03Earnings Release
More about the company
All news about PHARMAUST LIMITED
08/18PharmAust Limited Reports Earnings Results for the Full Year Ended June 30, 2..
CI
08/02PHARMAUST : Subsidiary Completes Construction of Flow Reactor in Western Austral..
MT
07/25PharmAust Limited Provides Monepantel and Monepantel Sulfone COVID-19 Anti-Vi..
CI
07/21PHARMAUST : Files Patent Application for Using Monepantel as Antiviral Drug
MT
07/12PHARMAUST : to Investigate Effect of Drug Candidate Monepantel in Cancer-Causing..
MT
07/11PharmAust and WEHI to Investigate HTLV-1 Viral Infections
CI
07/06PharmAust Limited Establishes Monepantel GMP Tablet Stability
CI
06/27Pharmaust Limited Achieves Phase IIB Dog Trial's Interim Clinical Endpoints
CI
06/02PHARMAUST : Receives Ethics Committee Approval for Phase 1 Nerve Disease Drug Tr..
MT
06/01PharmAust Receives Ethics Approval for Phase I Trial of Monepantel in Motor N..
CI
05/14PHARMAUST : Appoints New Principal Investigator for Pet Dog Lymphoma Trial
MT
04/27PHARMAUST : Receives Interim Analysis of Phase 2b Clinical Trial on Pet Dogs
MT
04/26PharmAust Limited Announces Phase IIb Canine Trial Identifies Therapeutic Win..
CI
04/07PHARMAUST : Receives R&D Tax Rebate; Shares Climb 5%
MT
04/07PHARMAUST : Confirms Antiviral Activity of Therapeutic Candidates Against SARS-C..
MT
More news
News in other languages on PHARMAUST LIMITED

- No features available -

More news
Chart PHARMAUST LIMITED
Duration : Period :
PharmAust Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMAUST LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Managers and Directors
Roger Aston Executive Chairman & Chief Executive Officer
Sam Michael Wright Secretary, Director & Director-Finance
Richard Mollard Chief Scientific Officer
Robert Charles Bishop Executive Director
Neville John Bassett Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
PHARMAUST LIMITED-17.14%20
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604